I’m an innovative biomedical graduate with an extensive background in biology and chemistry. additionally, I have gained five years of experience within pediatrics; my patients often suffered from complex, debilitating rare disorders.
I work along side a team consisting of multiple disciplines, research nurses to clinical physicians. Me and my team want to develop an array off cannabidiol (CBD) based products; and treatments to aid in the treatment of complex epilepsy developed in young children and as an analgesic alternative to aid in symptoms alleviation.
CBD, cannabidiol has been shown to have therapeutic properties. however, it is not currently readily available to many families that are desperate for many of the associated properties. through a culmination of my extensive background and my first hand experience of managing patients with debilitating disease. various parents and patients understand the necessity to ensure access to such topical treatments and how truly life changing they can be. I hope to promote the use and increase the availability to some of these treatments.
Two international clinical trials have been led and conducted by great Ormond street hospital. The study focussed on patients suffering from severe forms of epilepsy. it found that patients who where administered CBD showed reduced seizure activity by nearly 40 per cent in children with Dravet syndrome when compared with a dummy drug. Lennox Gastaut syndrome is characterised by particularly disabling seizures ‘drop attacks’ that impact quality of life; these seizures were significantly reduced by the drug.
The trials took place under strictly controlled circumstances, using the specific formulation pharmaceutically prepared Epidiolex (GW Pharma). Currently the trial results have been submitted for assessment by the regulatory bodies, the FDA (USA) and EMA (Europe), to consider whether a licence should be issued. We welcome this process which could pave the way for patient prescription.
Cannabis/hemp oils are available for purchase. While they often state that they contain acceptable and very low doses of the psycho-active element (Tetrahydrocannabinol or THC), they are not produced to a pharmaceutical standard and it has been demonstrated even different batches of the same product have variable content. As there is no evidence relating to dose, safety or interaction with other products, doctors cannot within their code of practice prescribe such products. Products with higher content of THC are not currently legal in the UK.
The funding generated will be used to develop several products. I will seek to develop a CBD spray for the treatment of epilepsy; which has been shown to be effective in complex epilepsies, more specifically Dravet syndrome and Lennox Gastaut syndrome. we will seek to cultivate topical treatments with analgesic properties, sterile for the use in the treatment of EB. furthermore, I hope to spread awareness of such holistic treatment; and prevent any more families with having to cope with intolerable life-debilitating severe seizures.